# Novo Nordisk

通过其用于糖尿病和肥胖症的GLP-1肽类疗法推动了前所未有的增长。

Source: https://cn.bioecon.ru/companies/novo-nordisk/
Updated: 2026-06-24

- 国家: Denmark
- 代码: NVO

## 可核验事实

| 事实 | 数值 | 来源 |
| --- | --- | --- |
| 融资 | 公司通过经营活动产生的现金流为资本支出及运营提供资金 | https://www.novonordisk.com/content/dam/nncorp/global/en/investors/irmaterial/annual_report/2026/novo-nordisk-form-20-f-2025.pdf, https://www.sec.gov/Archives/edgar/data/353278/000035327826000012/nvo-20251231_d2.htm |
| 产能 | Novo Nordisk是全球最大的胰岛素和GLP-1生产商，目前正在全球范围内大幅扩大产能，包括原料药（API）、无菌生产和灌装/精加工产能，以满足高需求 | https://www.globenewswire.com/news-release/2023/11/10/2778052/0/en/Novo-Nordisk-invests-more-than-42-billion-Danish-kroner-in-expansion-of-manufacturing-facilities-in-Kalundborg-Denmark.html, https://www.novonordisk.com/content/dam/nncorp/global/en/investors/irmaterial/annual_report/2026/novo-nordisk-form-20-f-2025.pdf, https://www.novonordisk.com/content/dam/nncorp/global/en/investors/irmaterial/cmd/2024/P3-Product-supply-updated.pdf |
| 认证 | DuraTouch设备已在所有欧盟国家获得CE认证标志 | https://www.novonordisk.com/content/dam/nncorp/global/en/investors/irmaterial/annual_report/2025/novo-nordisk-annual-report-2024.pdf |
| 监管批准 | Wegovy药片在美国获批（2025年12月）；Alhemo在美国获批；Ozempic说明书已更新；Awiqli和Rybelsus在美国、欧盟、日本及中国等多个地区获得多项批准 | https://www.novonordisk.com/content/dam/nncorp/global/en/investors/irmaterial/annual_report/2025/novo-nordisk-annual-report-2024.pdf, https://www.novonordisk.com/content/dam/nncorp/global/en/investors/irmaterial/annual_report/2026/novo-nordisk-form-20-f-2025.pdf, https://www.pharmamanufacturing.com/facilities/article/55360826/novo-nordisk-expands-irish-facility-with-500m-investment-to-manufacture-oral-glp-1s, https://www.sec.gov/Archives/edgar/data/353278/000035327826000012/nvo-20251231_d2.htm |
| 生产基地 | 主要生产基地包括丹麦（Kalundborg、Hillerød、Bagsværd、Gentofte、Odense、Hjørring）、美国（Clayton, North Carolina；New Hampshire）、法国（Chartres）、中国（天津）、爱尔兰（Athlone）及巴西（Montes Claros） | https://www.novonordisk.com/content/dam/nncorp/global/en/investors/irmaterial/annual_report/2026/novo-nordisk-form-20-f-2025.pdf, https://www.pharmamanufacturing.com/facilities/article/55360826/novo-nordisk-expands-irish-facility-with-500m-investment-to-manufacture-oral-glp-1s |
| 员工人数 | 根据2025年报告，全球员工超过69,500人，此前在2025年裁减了约9,000个职位 | https://www.novonordisk.com/content/dam/nncorp/global/en/investors/irmaterial/annual_report/2025/novo-nordisk-annual-report-2024.pdf, https://www.novonordisk.com/content/dam/nncorp/global/en/investors/irmaterial/annual_report/2026/novo-nordisk-form-20-f-2025.pdf |
| 营收 | 2025全年为3090.64亿丹麦克朗 | https://annualreport.novonordisk.com/2025/strategic-aspirations/financial-performance.html, https://www.sec.gov/Archives/edgar/data/353278/000035327826000012/nvo-20251231_d2.htm |

独立来源: globenewswire.com, pharmamanufacturing.com, sec.gov

## 技术

- [生物制药与生物医药](https://cn.bioecon.ru/technology/biopharmaceuticals-biomedicines/)